1. Rapid Generation of Reverse Genetics Systems for Coronavirus Research and High-Throughput Antiviral Screening Using Gibson DNA Assembly.
- Author
-
Zhou X, Liu H, Yang S, Dong X, Xie C, Ou W, Chen J, Yang Z, Ye Y, Ivanov KI, Liu L, Zou J, Li C, and Guo D
- Subjects
- Humans, Animals, Coronavirus genetics, Coronavirus drug effects, Mice, Drug Evaluation, Preclinical methods, SARS-CoV-2 genetics, SARS-CoV-2 drug effects, Genome, Viral genetics, Murine hepatitis virus genetics, Murine hepatitis virus drug effects, DNA, Complementary genetics, Coronavirus 229E, Human genetics, Coronavirus 229E, Human drug effects, Cell Line, Reverse Genetics methods, Antiviral Agents pharmacology, Chromosomes, Artificial, Bacterial genetics, High-Throughput Screening Assays methods
- Abstract
Coronaviruses (CoVs) pose a significant threat to human health, as demonstrated by the COVID-19 pandemic. The large size of the CoV genome (around 30 kb) represents a major obstacle to the development of reverse genetics systems, which are invaluable for basic research and antiviral drug screening. In this study, we established a rapid and convenient method for generating reverse genetic systems for various CoVs using a bacterial artificial chromosome (BAC) vector and Gibson DNA assembly. Using this system, we constructed infectious cDNA clones of coronaviruses from three genera: human coronavirus 229E (HCoV-229E) of the genus Alphacoronavirus, mouse hepatitis virus A59 (MHV-59) of Betacoronavirus, and porcine deltacoronavirus (PDCoV-Haiti) of Deltacoronavirus. Since beta coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV) represent major human pathogens, we modified the infectious clone of the beta coronavirus MHV-A59 by replacing its NS5a gene with a fluorescent reporter gene to create a system suitable for high-throughput drug screening. Thus, this study provides a practical and cost-effective approach to developing reverse genetics platforms for CoV research and antiviral drug screening., (© 2025 Wiley Periodicals LLC.)
- Published
- 2025
- Full Text
- View/download PDF